New study tracks safety of NF1 drug selumetinib in kids
NCT ID NCT05388370
First seen Mar 16, 2026 · Last updated May 22, 2026 · Updated 10 times
Summary
This study monitors the safety of selumetinib in children aged 3 to 18 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable tumors. Researchers will track heart function, bone growth, muscle enzymes, liver health, eye problems, and puberty development over time. The goal is to better understand real-world risks and long-term effects in routine medical care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Vienna, Austria
-
Research Site
Amiens, France
-
Research Site
Angers, France
-
Research Site
Bordeaux, France
-
Research Site
Lille, France
-
Research Site
Lyon, France
-
Research Site
Marseille, France
-
Research Site
Paris, France
-
Research Site
Rennes, France
-
Research Site
Strasbourg, France
-
Research Site
Toulouse, France
-
Research Site
Tours, France
-
Research Site
Vandœuvre-lès-Nancy, France
-
Research Site
Villejuif, France
-
Research Site
Dresden, Germany
-
Research Site
Duisburg, Germany
-
Research Site
Hamburg, Germany
-
Research Site
Hanover, Germany
-
Research Site
München, Germany
-
Research Site
Tübingen, Germany
-
Research Site
Petah Tikva, Israel
-
Research Site
Ramat Gan, Israel
-
Research Site
Tel Aviv, Israel
-
Research Site
Florence, Italy
-
Research Site
Genova, Italy
-
Research Site
Milan, Italy
-
Research Site
Padova, Italy
-
Research Site
Pavia, Italy
-
Research Site
Roma, Italy
-
Research Site
Torino, Italy
-
Research Site
Trieste, Italy
-
Research Site
Rotterdam, Netherlands
-
Research Site
Lisbon, Portugal
-
Research Site
Porto, Portugal
-
Research Site
Barcelona, Spain
-
Research Site
Madrid, Spain
-
Research Site
Málaga, Spain
-
Research Site
Santiago de Compostela, Spain
-
Research Site
Seville, Spain
-
Research Site
Basel, Switzerland
-
Research Site
Bern, Switzerland
-
Research Site
Lausanne, Switzerland
-
Research Site
Sankt Gallen, Switzerland
-
Research Site
London, United Kingdom
-
Research Site
Manchester, United Kingdom
-
Research Site
Newcastle upon Tyne, United Kingdom
Conditions
Explore the condition pages connected to this study.